Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA -0.89%48 Days Sales Outstanding is 89.97 as of Jun. 2026, which is 49% above its 10-year median of 60.51. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.32 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 835 Biotechnology companies, Idorsia ranks worse than 55.93% on this metric.
Idorsia's average Accounts Receivable for the
three
months ended in Jun. 2026 was CHF52.1 Mil. Idorsia's Revenue for the
three
months ended in Jun. 2026 was CHF52.9 Mil.
Hence, Idorsia's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 89.97.
The historical rank and industry rank for Idorsia's Days Sales Outstanding or its related term are showing as below:
XSWX:IDIA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.58 Med: 60.51 Max: 113.46
Current: 77.84
During the past 10 years, Idorsia's highest Days Sales Outstanding was 113.46. The lowest was 6.58. And the median was 60.51.
XSWX:IDIA's Days Sales Outstanding is ranked worse than 55.93% of 835
companies
in the Biotechnology industry
Industry Median: 68.95
vs XSWX:IDIA: 77.84
Idorsia's Days Sales Outstanding
increased
from Jun. 2025 (43.03) to Jun. 2026 (89.97).
Idorsia (XSWX:IDIA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Idorsia Days Sales Outstanding Related Terms
Idorsia Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Idorsia's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Idorsia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Idorsia's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a Days Sales Outstanding of 89.97 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Idorsia and its competitors. This is 49% above median its historical median of 60.51. Over the past decade, Idorsia's Days Sales Outstanding has ranged from 6.58 to 113.46. According to the industry distribution chart, Idorsia ranks #467 out of 835 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Idorsia's Days Sales Outstanding too high?
Idorsia's current Days Sales Outstanding of 89.97 is 49% above median its 10-year median of 60.51. Over the past 10 years, this metric has ranged from a low of 6.58 to a high of 113.46. The Biotechnology industry median Days Sales Outstanding is 68.95. Idorsia's value of 89.97 is 30.5% above this industry median. Based on the distribution chart, Idorsia ranks #467 out of 835 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #467 out of 835 companies for Days Sales Outstanding. This places Idorsia in the lower half of its industry. The industry median Days Sales Outstanding is 68.95. Idorsia's value of 89.97 is 30.5% above this benchmark. Historically, Idorsia's own Days Sales Outstanding has ranged from 6.58 to 113.46 over the past decade. While the company's 10-year median is 60.51 vs. the industry median of 68.95, Idorsia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.95, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Idorsia's current Days Sales Outstanding of 89.97 is 30.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Days Sales Outstanding is 89.97, which is 49% above median its own 10-year median of 60.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.32, compared to a current price of CHF5.55 — trading 139.2% above its estimated fair value. The current Days Sales Outstanding is 89.97, which is 49% above median its 10-year median of 60.51 and 30.5% above the Biotechnology industry median of 68.95. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Days Sales Outstanding is 89.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF5.55 is trading 139.2% above its estimated GF Value™ of CHF2.32.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Days Sales Outstanding: 89.97 (49% above median its 10-year median of 60.51)
GF Value™: CHF2.32 vs. price of CHF5.55 (139.2% above fair value)
Industry Position: 30.5% above the Biotechnology median (#467 of 835)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
